EMA — authorised 26 March 2021
- Application: EMEA/H/C/005127
- Marketing authorisation holder: Stemline Therapeutics B.V.
- Local brand name: Nexpovio
- Indication: NEXPOVIO is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
- Status: approved